ArticleAnnals of hematology2020

Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.

Murat Özbalak et al.PubMed ↗Publisher ↗

No numbers read from the abstract.